Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MYO vs RCEL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RCEL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

RCEL Overall Winner 6-Pillar Tally: MYO 2 – 3 RCEL (1 Tie) Matrix Metrics: MYO 3 – 7 RCEL

As of Nov 20, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). MYO carries a Unified Composite Score of 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin), whereas RCEL carries 45.6/100 (HOLD) at $15.62 (10.3x Forward P/E, -33.9% operating margin).

  • Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile RCEL trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MYO vs RCEL
MYO NYSE American
Myomo Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.81
-3.45% 1D
Market Cap $33.7M
TTM Revenue $46M
Forward P/E N/M
Beta / 30D Vol 2.22β · 107% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 43.0 Flow 58.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 29
RSI-14: 28.7 · SMA20: $1.16 · SMA50: $1.32
RCEL NASDAQ Head-to-Head Winner
Avita Medical, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$15.62
-2.31% 1D
Market Cap $506.7M
TTM Revenue $85M
Forward P/E 10.3x
Beta / 30D Vol 1.54β · 65% Vol
Unified Composite Score
45.6 / 100 HOLD
Tech 32.0 Fund 44.0 Flow 69.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (21.1% over 20 days), RSI 52
RSI-14: 51.5 · SMA20: $16.14 · SMA50: $13.96

6-Pillar Scorecard Institutional Category Breakdown (MYO 2 – 3 RCEL)

Columns: Metric · MYO · RCEL
1. Valuation Multiples RCEL
Forward P/E N/M 10.3x
Trailing P/E N/M 10.3x
PEG Ratio N/M N/M
EV / Revenue 0.9x 6.4x
2. Growth & Scale RCEL
Revenue Growth (YoY) +22.2% +53.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $46M $85M
Market Cap $33.7M $506.7M
3. Profitability & Quality MYO
Gross Margin 70.1% 82.4%
Operating Margin -21.8% -33.9%
Net Profit Margin -33.1% -42.6%
Return on Equity (ROE) -173.5% -1746.3%
4. Balance Sheet & Cash Flow MYO
Cash Generation (TTM) -$9.1M -$20M
Cash Flow Margin -20.0% -23.6%
Net Cash / Leverage $8.9M Net Debt (3.44x D/E) $37M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RCEL
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 266.0% (81st %ile) 84.7% (6th %ile)
Put/Call OI Skew N/A 0.18x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MYO (3) vs RCEL (7)
Institutional Metric MYO RCEL Criterion Row Edge
Market Capitalization
Scale
$33.7M $506.7M Larger Scale RCEL
Trailing P/E Ratio
Valuation
N/M 10.3x Lower Multiple RCEL
Forward P/E Ratio
Valuation
N/M 10.3x Lower Multiple RCEL
Revenue Growth (YoY)
Growth
+22.2% +53.1% Higher Growth RCEL
Operating Margin (TTM)
Profitability
-21.8% -33.9% Higher Margin MYO
Net Profit Margin
Profitability
-33.1% -42.6% Higher Margin MYO
Return on Equity (ROE)
Capital Efficiency
-173.5% -1746.3% Higher ROE MYO
52-Week Range Position
Momentum
16% ($1–$2) 82% ($3–$18) Stronger Trend RCEL
Beta / 30D Volatility
Risk Regime
2.22β · 107% Vol 1.54β · 65% Vol Lower Realized Risk RCEL
Unified Institutional Score
Composite Signal
40.1 / 100 (SELL) 45.6 / 100 (HOLD) Higher Composite RCEL
Trailing 12M Revenue (USD)
Operating Scale
$46M $85M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
70.1% 82.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev N/M PEG · 6.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.1M ($8.9M Net Debt (3.44x D/E)) -$20M ($37M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RCEL +34.82 pp
MYO: -33.52% · RCEL: +1.3%
3M Horizon RCEL +99.27 pp
MYO: -41.65% · RCEL: +57.62%
6M Horizon RCEL +263.07 pp
MYO: -22.02% · RCEL: +241.05%
1Y Horizon RCEL +283.14 pp
MYO: +12.3% · RCEL: +295.44%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MYO Revenue RCEL Revenue MYO Op. Margin RCEL Op. Margin Margin Leader
FY2018 $0M $0M -430.8% -1489.9% MYO
FY2019 $0M $10M -281.3% -466.4% MYO
FY2020 $10M $10M -138.5% -299.2% MYO
FY2021 $10M $30M -74.1% -90.8% MYO
FY2022 $20M $30M -68.6% -79.9% MYO
FY2023 $20M $50M -42.8% -85.1% MYO
FY2024 $30M $60M -19.1% -88.1% MYO
FY2025 $40M $70M -35.2% -59.4% MYO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MYO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 266.0%
IV Percentile 81st %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RCEL CONSOLIDATION
17d in phase · OBV NEUTRAL
Current IV 84.7%
IV Percentile 6th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RCEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MYO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $33.7M market capitalization and -21.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RCEL Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $506.7M market capitalization and -33.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MYO vs RCEL Key Questions & Quantitative Answers

As of Nov 20, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). MYO carries a Unified Composite Score of 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin), whereas RCEL carries 45.6/100 (HOLD) at $15.62 (10.3x Forward P/E, -33.9% operating margin). Technical & Structure Timing Caution: MYO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7); meanwhile RCEL trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RCEL leads the Growth & Scale pillar: MYO posts +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin), compared with RCEL at +53.1% YoY revenue growth and +0.0% YoY earnings growth on $85M TTM revenue (82.4% gross margin, -33.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MYO cumulative revenue shifted +300.0% while RCEL shifted +600.0%. In operating R&D and SG&A reinvestment, MYO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RCEL.

RCEL screens cheaper on headline valuation multiples. MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin), whereas RCEL trades at 10.3x Forward P/E, 10.3x Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-23.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MYO (-173.5% ROE) versus RCEL (-1746.3% ROE) capital efficiency.

In options market volatility and institutional positioning, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk). By comparison, RCEL carries 84.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.54β · 65% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.